Forma Therapeutics Holdings Inc

Forma Therapeutics — Technical Presentation (September 2021)

13 slides from Forma Therapeutics's technical presentation, September 2021

  1. Slide 1: Initial findings from an Ongoing First-in-Human Phase 1 Study of the CBP/p300 Inhibitor FT-7051

    Initial findings from an Ongoing First-in-Human Phase 1 Study of the CBP/p300 Inhibitor FT-7051 in Men with Metastatic Castration-Resistant Prostate Cancer Andrew J. Armstrong1, Michael S. Gordon2, Melissa A. Reimers3, Arif Hussain4, Vaibhav G. Patel5, Elaine T. Lam6, Alex Sedkov7, Von Potter7, Neal

  2. Slide 2: Financial relationships disclosure

    Andrew J. Armstrong, MD ScM FACP I have the following financial relationships to disclose: Consultant for: Astellas, Pfizer, Bayer, Janssen, Dendreon, BMS, AstraZeneca, Merck, Forma, Celgene, Clovis, Exact Sciences Grant/Research support from: NIH/NCI, PCF/Movember, DOD, Astellas, Pfizer, Bayer, Jan

  3. Slide 3: Background

    Background  CBP/p300 are co-activators of the androgen receptor (AR) relevant in metastatic castration-resistant prostate cancer (mCRPC) • CBP/p300 is overexpressed in advanced prostate cancer and is upregulated following androgen withdrawal1 • CBP/p300-mediated acetylation of AR, for example, stab

  4. Slide 4: The Courage Study

    The Courage Study (7051-ONC-101)  First-in-human, multicenter, phase 1, open-label study (NCT04575766)  Bayesian optimal interval (BOIN) design with an accelerated titration (AT) phase  Compared with the standard '3+3' design, the advantages of the BOIN design include a higher probability of sele

  5. Slide 5: Patient Population

    Patient Population Key Inclusion Criteria: Table 1: Summary of Baseline Characteristics  Diagnosis of mCRPC with either adenocarcinoma or mixed Parameter Median (range) or n (%) histology Age, years 70 (64-82)  At least 1 prior line of treatment for mCRPC (prior taxane therapy is allowed) Race: 

  6. Slide 6: Time on Treatment and Disposition

    Time on Treatment and Disposition Figure 3: Summary of Time on Treatment and Patient Disposition a a. Data cut-off 01-Sep-2021

  7. Slide 7: Safety

    Safety Table 2: Treatment-Emergent AEs (TEAEs) Reported in ≥2 Patients Grade 1-2 Grade 3-5 Overall Preferred Term (N = 8) (N = 8) (N = 8) Diarrhea 4 (50%) 0 4 (50%) Nausea 4 (50%) 0 4 (50%) Fatigue 3 (38%) 0 3 (38%) Blood creatinine increased 2 (25%) 0 2 (25%) Decreased appetite 2 (25%) 0 2 (25%) Di

  8. Slide 8: Pharmacokinetics

    Pharmacokinetics Figure 4: FT-7051 Plasma Concentration – Time Curve  FT-7051 is rapidly absorbed following oral administration Predicted efficacious exposure (Tmax: 1 - 2 hr) with an estimated elimination half-life (t1/2) of ~ 5 hr  Systemic exposure at 150 mg is approaching the predicted efficac

  9. Slide 9: Target Engagement Analysis

    Target Engagement Analysis  Reductions in nuclear H3K27Ac staining intensity in skin biopsy samples provide preliminary evidence of target modulation Figure 5: Change from Baseline in H3K27Ac Staining Intensity 0 25 mg H score (% Change) 50 mg C1D1 -10 100 mg 150 mg -20 C1D15 -30 C1D1 C1D15 Represe

  10. Slide 10: Patient Vignette

    Patient Vignette One patient in the 150 mg cohort experienced Gr3 hyperglycemia (DLT) and achieved a confirmed >50% decrease in PSA with continued decline and ongoing stable disease as of the data cutoff Figure 6: Single Patient PSA Over Time Baseline Characteristics  Demographics: 66-year-old whit

  11. Slide 11: Summary

    Summary  Available safety data suggest that FT-7051 is well tolerated • One DLT (hyperglycemia) reported for a patient receiving 150 mg FT-7051; patient was dose reduced (100 mg) and remains on study as of the data cutoff with a >50% reduction in PSA levels  Preliminary PK data indicate that FT-70

  12. Slide 12: Acknowledgments

    Acknowledgments  The authors thank the patients and their families for participation in the study  The authors thank David VanderWeele, MD, PhD and his team for their contributions to the study  This study is funded by Forma Therapeutics, Inc., Watertown, MA  FT-7051 is an investigational drug;

  13. Slide 13: References

    References 1. Comuzzi B, et al. (2004). J Pathol. 204(2):159-66. 2. Fu M, et al. (2000). J Biol Chem. 275(27):20853-60. 3. Faus H, Haendler B. (2008). J Cell Biochem. 104(2):511-24. 4. Debes JD, et al. (2005). Cancer Res. 65(13):5965-73. 5. Jin L, et al. (2017). Cancer Res. 77(20):5564-75. 6. Welti

Forma Therapeutics Holdings — Technical Presentation (September 2021) on 6ix